Effectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiences
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, cilt.31, sa.4, ss.534-539, 2019 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 31 Sayı: 4
- Basım Tarihi: 2019
- Doi Numarası: 10.1097/meg.0000000000001334
- Dergi Adı: EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.534-539
- Anahtar Kelimeler: hepatitis C virus, kidney diseases, PROD regimen, treatment, EXTRAHEPATIC MANIFESTATIONS, TRANSPLANT RECIPIENTS, HEMODIALYSIS-PATIENTS, ACTING ANTIVIRALS, DIALYSIS PATIENTS, HCV INFECTION, GENOTYPES 1, EFFICACY, OMBITASVIR/PARITAPREVIR/RITONAVIR, SAFETY
- İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet
Özet
Introduction Both hepatitis C virus infection (HCV) and chronic kidney disease (CKD) have been comorbid illnesses with increasing morbidity and mortality. The present study was conducted to present real-life experiences about treatment of HCV and CKD with a fixed-dose combination of paritaprevir 150 mg/day, ritonavir 100 mg/day as a booster, ombitasvir 25 mg/day, and dasabuvir 250 mg twice/day, the PROD regimen.